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We characterized the mechanism of fluoroquinolone-resistance in two isolates of
Streptococcus pseudopneumoniae having fluoroquinolone-efflux as unique mechanism
of resistance. Whole genome sequencing and genetic transformation experiments were
performed together with phenotypic determinations of the efflux mechanism. The PatAB
pump was identified as responsible for efflux of ciprofloxacin (MIC of 4µg/ml), ethidium
bromide (MICs of 8–16µg/ml) and acriflavine (MICs of 4–8µg/ml) in both isolates. These
MICs were at least 8-fold lower in the presence of the efflux inhibitor reserpine. Complete
genome sequencing indicated that the sequence located between the promoter of the
patAB operon and the initiation codon of patA, which putatively forms an RNA stem-loop
structure, may be responsible for the efflux phenotype. RT-qPCR determinations
performed on RNAs of cultures treated or not treated with subinhibitory ciprofloxacin
concentrations were performed. While no significant changes were observed in wild-type
Streptococcus pneumoniae R6 strain, increases in transcription were detected in the
ciprofloxacin-efflux transformants obtained with DNA from efflux-positive isolates, in the
ranges of 1.4 to 3.4-fold (patA) and 2.1 to 2.9-fold (patB). Ciprofloxacin-induction was
related with a lower predicted free energy for the stem-loop structure in the RNA of
S. pseudopneumoniae isolates (−13.81 and −8.58) than for R6 (−15.32 kcal/mol),
which may ease transcription. The presence of these regulatory variations in commensal
S. pseudopneumoniae isolates, and the possibility of its transfer to Streptococcus
pneumoniae by genetic transformation, could increase fluoroquinolone resistance in this
important pathogen.
Keywords: DNA topoisomerases, efflux pumps, fluoroquinolones, transcription regulation, Streptococcus
pseudopneumoniae
INTRODUCTION
Streptococcus pneumoniae (the pneumococcus) is a main human pathogen causing
community-acquired pneumonia, meningitis, bacteremia, and otitis media (Obaro, 2000). It has
been estimated that one million children 5 years of age and under die annually of pneumococcal
infections (World Health Organization, 2007). Pneumococcal resistance to antibiotics normally
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used to treat pneumococcal infections, such as beta-lactams
and macrolides has spread worldwide (Liñares et al., 2010).
Nowadays, the fluoroquinolones (FQs) levofloxacin (LVX) and
moxifloxacin (MXF) are indicated for the treatment of adult
patients with pneumonia (Mandell et al., 2007). Although FQ-
resistance in S. pneumoniae is low (<3%) in Europe (Riedel
et al., 2007; Domenech et al., 2014), it is higher in Asia (10.5%,
Ip et al., 2007), and in Canada (7.3%, Adam et al., 2009).
However, an increase in resistance may occur if the use of
these drugs increases (Chen et al., 1999). The intracellular
targets of the FQs are the DNA topoisomerase enzymes gyrase
and topoisomerase IV, which control DNA topology, solving
topological problems associated with replication, transcription
and recombination (Champoux, 2001). In S. pneumoniae, most
FQs act on topoisomerase IV as a primary target (Muñoz and
de la Campa, 1996; Morrissey and George, 1999). FQ-resistance
in this bacterium occurs mainly by the alteration of their
DNA topoisomerases. This can occur either by point mutation
or by intraspecific (Stanhope et al., 2005), or interspecific
recombination with the genetically related streptococci of the
mitis group, commensal microorganisms of the oral cavity
(Ferrándiz et al., 2000; Balsalobre et al., 2003; Stanhope et al.,
2005). Some FQ-resistant (FQ-R) mutations impose a fitness
cost to S. pneumoniae (Rozen et al., 2007; Balsalobre and
de la Campa, 2008). Compensation of this cost in isolates
carrying recombinant topoisomerase genes (Balsalobre et al.,
2011) would envisage a future spread of these resistant isolates.
These recombinant isolates are originated by genetic interchange
with chromosomal DNA of other streptococci of the mitis
group. Among them, the species most genetically close to
S. pneumoniae are Streptococcus mitis, Streptococcus oralis,
and Streptococcus pseudopneumoniae (Arbique et al., 2004).
Homologous recombination among streptococci of the mitis
group plays a role in the evolution of antibiotic resistance in these
bacteria. Recombination had played a role in antibiotic resistance
in S. pneumoniae. Recombinant genes in the topoisomerase
genes (Ferrándiz et al., 2000; Balsalobre et al., 2003), in the
genes of penicillin-binding proteins (Dowson et al., 1990) and
in the rpoB genes of rifampicin-resistant strains (Ferrándiz et al.,
2005) have been identified. Recombination and the spread of a
few international clones are central factors generating antibiotic
resistance in S. pneumoniae.
Alternatively, pumping of FQs out of the cell has also a
role on resistance in S. pneumoniae. FQ-efflux is present in
S. pneumoniae clinical isolates (Brenwald et al., 1998; de la
Campa et al., 2004, 2009) and also in streptococci of the mitis
group (Ferrándiz et al., 1999). PmrA, which belongs to the major
facilitator superfamily (MFS), was the first pump described in
S. pneumoniae, whose inactivation in a FQ-R isolate derived
from the laboratory strain R6, restored FQ sensitivity (Gill et al.,
1999). Further studies pointed out the existence of other FQ-
efflux pumps (Pestova et al., 2002; Brenwald et al., 2003). The role
of PmrA in FQ-resistance in clinical isolates has not been proved,
since no correlation has been observed between pmrA expression
and FQ-efflux (Piddock et al., 2002). A systematic deletion of
11 putative efflux pumps in S. pneumoniae TIGR4 showed an
association between deletion of the ABC transporter PatAB
and hypersusceptibility to ciprofloxacin (CPX), acriflavine, and
ethidium bromide (Robertson et al., 2005). The same phenotype
was observed in FQ-R clinical isolates (Garvey et al., 2011). The
patA and patB genes showed CPX-induced overexpression in
both a FQ-R laboratory mutant (Marrer et al., 2006), and in
clinical isolates (El Garch et al., 2010). Further studies associated
mutations in a RNA stem-loop structure located upstream of
patAB with both the overexpression of these genes and FQ-
resistance (Baylay and Piddock, 2015). Likewise, the homolog
of PatAB in the zoonotic pathogen Streptococcus suis, named
SatAB, has been shown to be constitutively overexpressed and
to confer CPX resistance to a clinical isolate (Escudero et al.,
2011). The satAB genes are regulated by the satR repressor,
which is located upstream of these genes and cotranscribed with
them (Escudero et al., 2013). These studies stablished a role for
PatAB in FQ-resistance in clinical isolates of S. pneumoniae. In
addition, a role in LVX and MXF efflux has been stablished
for the multi-antimicrobial extrusion family (MATE) DinF
transporter in a pneumococcal laboratory strain (Tocci et al.,
2013).
Among the FQ-R (considering those with CPX MICs
≥4µg/ml) S. pneumoniae isolates characterized in our laboratory
in two epidemiological studies, one performed during 1991 to
2001 (Ferrándiz et al., 2000; Balsalobre et al., 2003), and the other
in 2002 (de la Campa et al., 2004), we selected 14 isolates carrying
DNA topoisomerase genes with high nucleotide sequence
variations (>4%). Seven out of these 14 isolates were further
classified as S. pseudoneumoniae (Balsalobre et al., 2013). Two of
them, 5305 and CipR-71, which did not carry mutations in the
quinolone-resistance determining regions of their topoisomerase
genes, showed efflux as a single mechanism of FQ resistance.
As far as we know, there are no other descriptions of FQ-
resistant S. pseudoneumoniae. In this study we aimed to identify
the efflux mechanisms of FQ-resistance of these isolates. Whole
genome sequencing and genetic transformation experiments
were performed together with phenotypic determination of FQ-
efflux.
MATERIALS AND METHODS
Bacterial Strains and Conditions for
Growth and Transformation
Streptococcus pneumoniae and Streptococcus pseudopneumoniae
strains were grown as static cultures either in a casein
hydrolysate based medium (AGCH) supplemented with 0.3%
sucrose and 0.2% yeast extract (A+SY) (Lacks et al., 1986) or
in Tod-Hewitt (Becton Dickinson) with 0.5% of yeast extract
(THY). MICs of ethidium bromide, acriflavine and FQs were
determined by agar-dilution (for S. pseudopneumoniae 5305) or
by macrodilution following the methods of the CLSI (Clinical
Laboratory Standards Institute, 2008) using 2-fold dilutions in
A+SY liquid medium, with an inoculum of 5 × 105 cells per
well. The efflux inhibitor reserpine (Gill et al., 1999; Garvey et al.,
2011) was used at a final concentration of 10µg/ml, which has
been shown to inhibit ethidium bromide, acriflavine, and CPX
efflux in streptococci of the mitis group (Ferrándiz et al., 1999).
S. pneumoniae R6 was used as the recipient in transformation
experiments. Competent cultures containing 9 × 106 CFU/ ml
were incubated with 0.1 µg/ ml of DNA during 40min at
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30◦C and then at 37◦C for 90min before plating. Colonies were
counted after 24 h of growth at 37◦C in a 5% CO2 atmosphere in
A+SY media plates containing 1% agar and CPX at 2 µg/ ml. No
transformation refers to experiments in which no colonies were
observed when 100 µl of the transformation mixture was plated,
which gave a frequency <1 × 101. DNA used as control was the
chromosome of T5305 that yielded 1.1× 103 transformants/ml.
Whole-Genome Sequencing
Two S. pseudopneumoniae clinical isolates, 5305 and CipR71,
and two S. pneumoniae strains, an R6 transformant with 5305
chromosomal DNA, named S. pneumoniae T5305 and our
laboratory S. pneumoniae R6 strain, were subjected to whole
genome sequencing. Genomic DNA samples were prepared from
mid-log phase cultures using the CTAB protocol (Wilson, 1994).
Sequencing was performed either in a 454 Life Sciences GS-
FLX+ system, Roche (5305 and CipR71) or in an Illumina
NextSeq 500 system (T5305 and our laboratory R6). DNA for
454/Roche library preparation was fragmented by nebulization
and posterior quantification, emulsion PCR and sequencing
performed as recommended by the manufacturer. Libraries for
Illumina sequencing were obtained following the transposon-
mediated Nextera XT library preparation kit (Illumina) and
paired-end sequenced with a 2 × 150 protocol. De novo or
reference aided (S. pneumoniae R6) assemblies were performed
using Newbler 3.0 (Roche) with default settings. sff files from
454/Roche and fastq files from Illumina were used as input
sequences, respectively. Assembly metrics are shown in Table 1.
Coverage was calculated by dividing total bases used in the
computation by the size of the final alignment following the
Lander/Waterman equation (Lander and Waterman, 1988).
Gene and Protein Analysis
Coding sequences were predicted by Prodigal V.2.6.3 with default
settings (Hyatt et al., 2010). S. pneumoniae pump gene sequences
(Tocci et al., 2013) were detected in S. pseudopneumoniae
genomes by BLASTN using S. pneumoniae TIGR4 sequences as
queries and applying bidirectional thresholds of ≥80% identity
and an alignment length over ≥80% of the protein sequences.
Promoter-containing sequences of S. pseudopneumoniae isolates
were extracted as the 100 upstream nucleotides of the pump
gene, or, in the case of genes in operons, the 100 upstream
nucleotides of the first gene of the operon. The RNA stem-loop
TABLE 1 | Characteristics of the whole genome sequences.
Strain Total readsb Contig Mean
size coverage
N◦ N◦ bases N50c
S. pseudopeumoniae 5305 89,125 129 2,160,666 44,063 21
S. pseudopeumoniae CipR71 79,852 101 2,141,171 74,053 20
S. pneumoniae T5305 2,809,086 221 1,976,262 32,462 181
S. pneumoniae R6a 1,450,983 52 2,007,471 91,805 84
aOur laboratory S. pneumoniae R6 strain.
bThe % of aligned reads was ≥98.60 and of the aligned bases was ≥97.56.
cMinimum contig length needed to cover 50% of the genome.
structure was predicted by using the RNA-fold web server
(http://rna.tbi.univie.ac.at/cgi-bin/RNAWebSuite/RNAfold.cgi).
Gene organization of operons was downloaded from the DOOR
database (Mao et al., 2009), using the S. pseudoneumoniae IS7493
strain as reference. Protein and nucleotide sequences were
aligned with Clustal Omega (Sievers et al., 2011).
Nucleotide Sequence Accession Numbers
The sequencing data have been deposited at the whole genome
sequencing database linked to the BioProject ID PRJNA386436.
PCRs, RNA Extraction and Quantitative
Real Time PCR (RT-qPCR) Procedures
Primers used for PCR amplifications and sequencing are shown
in Table 2. Platinum R© Taq High Fidelity (Invitrogen), was used
for PCR amplifications in the following conditions: an initial
cycle of 2min denaturation at 94◦C; 30 cycles of denaturation
at 94◦C for 30 s, annealing at 55◦C for 30 s and extension at
68◦C for 1min per kb of PCR product. Primers used for PCR
amplifications and sequencing are shown in Table 2. To quantify
the relative expression of hexA, patA, and patB, a procedure
previously described (El Garch et al., 2010) was used. Briefly, R6-
derivative strains were grown overnight at 37◦C in 5% CO2 in
Mueller-Hinton agar plates supplemented with 5% defibrinated
sheep blood (Becton Dickinson). Bacteria were suspended in 5ml
of THY, grown to OD620nm = 0.2, diluted 10-fold into 25ml of
THY and grown to OD620nm = 0.2 to 0.4 (2–4 × 10
8 cells). At
this point, cultures were split into two parts; one part was grown
during 4 h in the presence of CPX at 0.5 × MIC for each strain,
and the other was grown in its absence. Cells were collected
by centrifugation and their total RNA was extracted with an
RNeasy mini kit (Qiagen), with 3 DNase I (Qiagen) treatments,
according to the manufacturer’s instructions. Synthesis of cDNAs
were carried out in 20-µl reactions containing 0.5–5 µg of
RNA, 0.5mM of each deoxynucleoside triphosphate, 2 pmol
of hexanucleotide random primers, 40U of the RNaseOUT
RNase inhibitor (Invitrogen), 200U of SuperScript IV reverse
transcriptase (Invitrogen), and 2U of RNase H− (Invitrogen),
in the buffer recommended by the manufacturer. These cDNAs
were used in RT-qPCR amplifications (Light cycler 480, Roche).
The total volume in each reaction was 20 µl and contained 2 µl
of cDNA, 0.4µM of each primer, and 10 µl of Sso Advanced
Universal SYB Green Supermix (BioRad). The program had
one initial denaturation cycle of 4min at 94◦C followed by
42 cycles of three steps: denaturation (30 s at 94◦C), annealing
(30 s at 54◦C), and elongation (30 s at 68◦C). Oligonucleotide
pairs used were: PatARTF/PatARTR (patA); PatBRTF/ PatBRTR
(patB), HexARTF/HexARTR (hexA). The amount the RT-PCR
products was calculated with a standard curve for each amplicon.
Assays were performed in triplicate and normalized against the
signal from a 16S rDNA internal control (oligonucleotide pair
rDNAF/rDNAR).
Transcription Start Site Determination
5′ RACE (rapid amplification of cDNA ends) method was
performed using total RNA extracted from strain TCipR71.2
treated with CIP at 0.5 × MIC as template. A total of 12
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TABLE 2 | Oligonucleotides used in this work.
Name Sequence (5′-3′)a Nucleotide positonsb
HexAF22 GGCATGCAACAGTATGTGG 64 to 82 of hexA
HexAF757 CCAAGATTGCTGGCTTGCCAGC 2,330 to 2,352 of hexA
HexAR755 CCAGCAATCTTGGCAACATGG Complementary to 2,342 to 2,321 of hexA
HexARTF GCTCTTTCGGATGGGTGATTT 113 to 134 of hexA
HexARTR GCTTACTGCTATCGACCACTGT Complementary to 378 to 400 of hexA
HexARTF2 CATCCTATCCTAGCAGAATTAGC 2,479 to 2,501 of hexA
HexARDown TTATAGTTTCTGTTTTAACTCTAC Complementary to 2,551 to 2,574 of hexA
GuaR80 GGATGAACATTTTGGCCTCCTG Complementary to 474 to 452 of guaA
PatAF17 GATGACAGGCTTGATGGTTGC 53 to 74 of patA
PatAR17 GCAACCATCAAGCCTGTCATC 74 to 53 of patA
PatBFUp CGCATGCAGACTTGGTTGCCA −827 to −806 of patB
PatARDown TGGCAACCAAGTCTGCATGCG Complementary to −806 to −827 of patB
PatBRDown TAGGACAAGAAAAAGCAGCCCC Complementary to −73 to −51 of guaA
PatARTF TGATGACAGGCTTGATGGTT 52 to 72 of patA
PatARTR AACGACTAGATTTCCCGCAT Complementary to 333 to 313 of patA
PatARTR2 AACCATCAAGCCTGTCATCA Complementary to 53 to 72 of patA
PatARACE1 CTCCTTGGGCAATATAGGCTGC Complementary to 220 to 241 of patA
PatARACE2 CCAATCAACCAAGCCCCGATAC Complementary to 152 to 173 of patA
PatBRTF GCACCCCATTGGCTTTCCTTA 523 to 542 of patB
PatBRTR GCACGCGCTCATTTTGTTCA Complementary to 715 to 695 of patB
rDNAF GGTGAGTAACGCGTAGGTAA 101 a 120 of 16SrDNA
rDNAR ACGATCCGAAAACCTTCTTC Complementary to 407 to 426 of 16SrDNA
RibAF135 GCTTCTGTGTGTCCATTTCTTTC 411 to 434 of ribA
RACE 5
′
GATATGCGCGAATTCCTGTAG 1 to 21 of RNA adaptor
RACE5
′
Inner AATTCCTGTAGAACGAACACTAGAA 11 to 35 of RNA adaptor
RNA adaptor GAUAUGCGCGAAUUCCUGUAGAACGAACACUrArGrArArArGrArArA
TagAR131 GGGGCTTGGCGATAATCAGG Complementary to 413 to 393 of tagA
aThe “r” before the base indicated that it was a ribonucleotide.
bNucleotide and amino acid numbering refers to the genes and proteins obtained from the S. pneumoniae R6 sequence, with the first nucleotide or amino acid at position 1.
µg of RNA were used, 6 µg were treated with Tobacco acid
pyrophosphatase (TAP) to hydrolyze specifically 5′-triphosphate
from primary transcripts, and to subsequently be ligated
to the 3′-hydroxyl group of an RNA oligonucleotide (RNA
adaptor, Table 2). The remaining 6 µg of total RNA were
not treated with TAP and followed the same post-treatment.
cDNAs were synthesized from these RNAs using SuperScript
IV Reverse Transcriptase (Invitrogen) following manufacturer
recommendations and used as templates in PCR reactions with
primers PatARACE1 and RACE5′ (Table 2) as detailed in PCRs,
RNA Extraction and Quantitative Real Time PCR (RT-qPCR)
Procedures. PCR products were purified with MinElute PCR
purification kit (Quiagen) and used as templates for a second
PCR reaction using primers PatARACE2 and RACE5′Inner
(Table 2). PCR products were separated in a 2%Metaphor (FMC
Bioproducts) agarose gel and the band that appeared in the
sample treated with TAP, and did not appear in the untreated
sample, was isolated from the gel with MinElute Gel Extraction
Kit (Qiagen). DNA was sequenced using primer PatARACE2 to
determine the transcription start site, which was the first base 5′




The MICs of isolates 5305 and CipR71 to FQs and some
dyes in the presence and absence of the efflux pump inhibitor
reserpine were compared to three efflux-negative control strains:
S. pneumoniae R6, S. pseudopneumoniae CCUG48465, and the
S. pseudopneumoniae type strain CCUG49455T. No significant
differences in the MICs of LVX, CPX, ethidium bromide and
acriflavine in the presence or absence of reserpine were observed
in the control strains. However, the two S. pseudopneumoniae
clinical isolates, which showed 8- to 32-fold higher MICs of
these drugs in the absence of reserpine than the control strains,
essentially behave like the control strains in the presence of the
pump inhibitor (Table 3). Reserpine it is assumed not to affect
growth of the strains at the concentration used (10 µg/ ml), since
the MICs of reserpine for S. pneumoniae have been described to
be 60µg/ml (Garvey and Piddock, 2008). These results suggested
the existence of an efflux pump in S. pseudopneumoniae isolates
5305 and CipR71.
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TABLE 3 | Susceptibilities of strains to fluoroquinolones and efflux pump substrates.
Strain MIC (µg/ml)a
LVX LVX+Rs CPX CPX+Rs EtBr EtBr +Rs Acr Acr+Rs
S. pneumonia R6 0.25 0.25 0.5 0.5 1 0.25 1 0.5
S. pseudopneumoniae CCUG49455T 0.25 0.25 0.5 0.25 0.5 0.25 0.5 0.25
S. pseudopneumoniae CCUG48465 0.5 0.5 0.5 0.25 0.5 0.25 0.5 0.25
S. pseudopneumoniae 5305 1 0.5 4 0.5 16 0.25 8 1
S. pneumonia T5305 1 0.5 4 0.25 16 0.25 4 1
S. pneumonia T5305.1 1 0.5 4 0.25 16 0.25 8 1
S. pneumonia T5305.2 1 0.5 4 0.25 16 0.25 4 1
S. pseudopneumoniae CipR71 1 0.5 4 0.25 8 0.25 4 1
S. pneumonia TCipR71.2 1 0.5 4 0.25 16 0.25 4 1
aAcr, acriflavine; CPX, ciprofloxacin; EtBr, ethidium bromide; LVX, levofloxacin; Rs, reserpine. MICs are the average of at least three determinations, which did not differ more that 2-fold
dilution. Figures in bold indicate MICs at least 2 dilutions higher in the absence of reserpine than those of R6 and the S. pseudopneumoniae CCUG48465, and S. pseudopneumoniae




We analyzed the genome sequences of the 5305 and CipR71
resistant strains and compared them with those of S. pneumoniae
and S. pseudopneumoniae isolates, paying special attention to
those coding for the 11 pneumococcal antimicrobial pumps
(Tocci et al., 2013). S. pseudopneumoniae isolates carried
nine of these pumps, coded by 14 genes, given that they
are constituted by complexes in some cases. Amino acid
sequences of the permease subunits and the sequences covering
the 100 nucleotides upstream of the coding sequence (or
of the first coding sequence of the operon) were compared
(Table 4). Subtle differences were detected in the sequences of
these pumps. However, simultaneous alterations, i.e., alterations
common to both S. pseudopneumoniae isolates with an efflux
phenotype (CipR71 and 5305) respect to the efflux-negative
S. pseudopneumoniae type strain ATCC BAA-960, were found
only in the coding sequences of five of these genes (affecting four
pumps), which essentially ruled out the possible involvement
of the nine remaining genes in the efflux phenotype. The most
remarkable efflux-linked determinants were the coding sequence
of the ABC transporter SP_1357 (11 residue changes) and the
regulatory sequence of the patAB operon. Both proteins are part
of the Drug Exporter-4 family of the Transport Classification
Database (TCDB id: 3.A.1.135). The enhanced CPX efflux of
isolates 5305 and CipR71 could be attributed either to higher
substrate affinity/enhanced activity produced by the residue
changes in SP_1357, by an up-regulation of the PatAB pump, or
by a combination of both. To discern between these possibilities,
genetic transformation experiments were carried out as described
below.
Genome Sequence of the R6 Transformant
(T5305) Revealed Two Recombination
Regions
Streptococcus pneumoniae R6 was transformed with
chromosomal DNA of S. pseudopneumoniae 5305. One
transformant, T5305, was selected. T5305 had a CPX MIC of
4µg/ml, this MIC was equivalent to that of S. pseudopneumoniae
5305. In addition, 5305 and T5305 exhibited the same efflux
phenotype to CPX, ethidium bromide and acriflavine (Table 3).
The analysis of the S. pneumoniae T5305 genomic sequence
showed 420 nucleotide changes with respect to the sequence
of S. pneumoniae R6 present in the NCBI data base (Accession
number: NC_003098.1). To discard spurious mutations, our
laboratory R6 strain was also sequenced, showing 21 SNPs with
respect to the NCBI sequence (data not shown). These changes
were not considered, then, a total of 399 changes were attributed
to the recombination event. These changes were unevenly
distributed, 353 of them were located in a 7184 bp region (4.8%
of variation) covering the spr1884 to spr1888 genes (guaA-
patB-patA-hexA); 45 in a 3540 bp region (1.2% of variation)
covering the spr0162 to spr0166 genes (ribA-ribC-ruvA-tag); and
1 point mutation in spr1903 (galU). These results demonstrate
that the recombination event yielding T5305 occurred in two
regions: spr0162-0166 and spr1884-1888 (Figure 1). This was
very likely due to its close spatial proximity considering both
recombined regions are at the same distance to the chromosome
replication origin, a factor that may increment inter-replicore
gene transference.
The Region Involved in FQ Efflux Includes
the Upstream patA Region
To reveal the role of the nucleotide changes present in T5305
in FQ-efflux, diverse DNA fragments were amplified from
this strain by PCR with specific oligonucleotides (Table 2).
These fragments were used as donor DNAs in transformation
experiments with R6 as receptor, and transformants selected at
2µg/ml of CPX. Transformation experiments were performed as
described under Materials and Methods, being the frequencies
of transformation in the range of 1 to 7 × 103 transformants/
ml. DNA fragments covering the spr0162-0166 genes or the
galU mutation did not result in transformants at elevated CPX
concentrations, discarding the role of these genes in CPX-
resistance. In contrast, two overlapping PCR fragments from
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TABLE 4 | Comparison of coding and regulatory sequences of S. pseudopneumoniae homologs to S. pneumoniae pumps associated to drug efflux.
Operon or genea Transporterb Coding sequencec Upstream sequenced
Gene % Identity N◦ of simultaneous changes %Identity (indels) N◦ of simultaneous SNPs
5305 CipR71 5305 CipR71
SP0967-72 MFS-PmrA SP0972 97.3e 100f 0 100 (0) 100 (0) 0
SP1116 ABC SP1116 95.9 100 0 96 (0) 98 (0) 0
SP1166 MATE SP1166 98.9 98.2 1 100 (0) 100 (0) 0
SP1359-7 ABC-MDR1 SP1358 98.3 100 0 95 (0) 98 (0) 0
SP1357 96.6 98.1 11 – – –
SP1840 100 100 0 – – –
SP1840-39 ABC-MDR1 SP1839 99.5 100 0 100 (0) 100 (0) 0
SP1919-8 ABC SP1919 98.4 99.3 2 96 (0) 97 (0) 0
SP1939 96.1 100 0 – – –
SP1939 MATE-DinF SP2065 95.8 100 0 100 (0) 100 (0) 0
SP2065 MATE SP2075 98.9 99.2 2 95 (0) 100 (0) 0
SP2075-3 ABC-MDR1-PatAB SP2073 98.0 99.3 2 94 (1) 95 (1) 3
aLoci of TIGR4 (GenBank accession number AE005672), operon indicates the genes included in the same transcriptional unit, as loaded from the DOOR database (39).
bATP binding cassette (ABC); multiantimicrobial extrusion (MATE); major facilitator superfamily (MFS).
c Identities (%) in the coding sequence (amino acid residues) of the permease subunits with respect the S. pseudopneumoniae type strain ATCC BAA-960.
dThe sequences positions −101 to −1 of the gene/ first gene of the operon were compared. −, no applicable.
eS. pseudopneumoniae 5305 has 1-30 and 325-393 deletions for this protein.
fS. pseudopneumoniae CipR71 has a 80 residues insertion in the C-terminus (394-473).
the spr1884-1888 region transformed R6 with high efficiency
(Figure 1). One of the amplicons covers the C-terminus of
hexA and the intergenic hexA-patA region plus patA, whereas
the other covers the same regions but including patB. In
accordance, PCR products including most of the hexA and
patA sequences were also able to transform to CPX resistance.
The smallest fragment able to transform R6 to CPX resistance
was obtained by amplification with oligonucleotides HexAF757
and PatAR17. Likewise, PCR products obtained from isolate
CipR71 with the same oligonucleotide pairs also transformed
R6 with high efficiency. In contrast, DNA fragments containing
hexA, patA, patB, or guaA coding sequences, but not the
hexA-patA intergenic region, were unable to transform R6 to
CPX-resistance. In addition, a fragment covering hexA from
residue position 22 to the stop codon, which was obtained from
S. pseudopneumoniae strains 5305 and CipR71, did not transform
to CPX-resistance (Figure 1). Three resistant transformants, two
obtained with PCR products from 5305 (T5305.1 and T5305.2)
and one from CipR71 (TCipR71.2) were selected for further
studies. Their nucleotide sequences were identical to that of
the donor 5305 and CipR71 strains and their MICs were
equivalent to that of their parental DNA donors (Table 3). All
these results demonstrated that the region involved in FQ-
efflux in the S. pseudopneumoniae strains T5305 and CipR71
was that included between oligonucleotides HexARDown and
PatAR17 (Figure 2A). This region contains the intergenic hexA-
patA region and the first 74 nucleotides of patA. No amino acid
changes were predicted in PatA between R6, 5305 and CipR71
or the derived R6-transformants. The intergenic hexA- patA
region has been previously stablished to be involved in FQ-
efflux in SPN (Baylay and Piddock, 2015). A promoter with a
canonical −35 box and an extended −10 sequence was observed
in all strains. We determined the transcription start site by
RACE 5′ PCR as described in materials and methods, which
was located eight nucleotides downstream of extended −10
sequence (Figure 2B). The main differences were found between
the extended −10 sequence and the patA initiation codon, in
which the two S. pseudopneumoniae FQ-resistant strains CipR71
and 5305 showed a 3-nt insertion (GCT) or a 3-nt deletion
(GGA), respectively. A stem-loop structure could be predicted by
RNA-fold in this region with a free energy of −15.32 kcal/mol
for R6 (Figure 2C). The nucleotide changes observed in CipR71
and 5305 CPX-resistant isolates are predicted to lower the free
energies of these structures to −8.58 kcal/mol for 5305 and
−13.82 kcal/mol for CipR71. These changes in the stability of the
stem-loop structures could cause alterations in the transcription
of the downstream patA and/ or patB genes.
Transcription of patA Is Induced by CPX
To quantify the induction produced by CPX, RT-qPCR
experiments were performed with RNAs of cultures treated or
not treated with a subinhibitory CPX concentration. These assays
showed that the expression of both patA and patB in the R6-
derivative strains was induced by CPX. While no significant
changes were observed in R6, increases in patA and patB were
detected in all strains with an efflux phenotype. These increases
were in the range of 1.4 to 3.4-fold for patA, and of 2.1 to 2.9-
fold for patB. However, the transcription of hexA did not show
significant differences between R6 and its transformant-derived
strains, being in the range of 0.7 to 1.3-fold (Figure 3).
DISCUSSION
In this study we have characterized the FQ-efflux phenotype
of two S. pseudopneumoniae isolates, 5305 and CipR-71, which
do not have mutations in their DNA topoisomerase genes.
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FIGURE 1 | Genomic map of the recombination regions of S. pneumoniae T5305. Genes are represented as arrows, indicating the level of nt divergence with respect
SPN R6. PCR fragments used in transformation experiments, together with their corresponding primers (white arrows, not draw to scale), are indicated. The intergenic
region between patA and patB is 773-bp in S. pneumoniae, but is absent in S. pseudopneumoniae isolates (indicated by a crosshatched line). Black boxes and white
boxes indicate PCR fragments yielding or not yielding CPX-R transformants, respectively. Asterisks indicate recombination points.
Changes in the regulatory sequences of the patAB operon
were found. The presence of these changes in two genetically
diverse isolates is significant. CipR71 is genetically closer to the
S. pseudopneumoniae reference strain than to 5305, as inferred
from the higher identity between pump sequences (Table 4)
and the fact they share three out of seven alleles (ddl, gki
and recP) used in multilocus sequence typing, whereas 5305
shares none. These changes would have been acquired by
horizontal transfer and/or convergent evolution processes. In
addition, these sequence features were absent or very unusual
in S. pseudopneumoniae as corroborated in the only complete
genome fully sequenced in this species—IS7493—and the 29
S. pseudopneumoniae strains present in the whole-genome
shotgun contig database of the NCBI that were screened. In
addition, other pumps, whose function has not been determined,
were detected in the CPX-efflux isolates (data not shown).
The analysis of the T5305 sequence, together with
transformation experiments, showed that the region involved
in CPX-efflux, which has the greatest variation by far with
respect to R6, was a 7184 bp region covering spr1884 to
spr1888 genes (guaA-patB-patA-hexA). The region involved
was further reduced to 247-bp, independently of the donor
DNA strain (5305 or CipR71). This region contains the last
24 nt of hexA, the intergenic hexA-patA region, and the first
74 nt of patA. No amino acid changes were predicted in
HexA or PatA between R6, 5305 and CipR71, and therefore
we conclude that the intergenic hexA- patA region previously
established to be involved in FQ-efflux in S. pneumoniae (Baylay
and Piddock, 2015), is also involved in S. pseudoneumoniae.
Then, the enhanced CPX efflux of isolates 5305 and CipR71
could be attributed to the regulation of the expression of the
patAB operon, and not to residue changes in the proteins of
the pump. The main difference was found in the sequence
between the extended−10 region and the patA initiation codon,
in which a 3-nt insertion (GCT) in the case of CipR71, or a
3-nt deletion in the case of 5305, were observed. These indels
were not found in the patAB upstream regions of the reference
genome or in a set of S. pseudoneumoniae genomes in the
whole-genome shotgun database. Since this genome set include
diverse isolates from disparate geographical origins and sample
sources, these indels—and subsequently the efflux phenotype
that provides—can be considered as an unusual feature selected
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FIGURE 2 | Sequence of the region involved in CPX resistance in S. pseudopneumoniae isolates, determination of the patAB transcription star site, and putative
structures in the patA upstream RNAs. (A) Sequence included between oligonucleotides HexARDown and PatAR17, which are boxed, is shown in full for
S. pneumoniae R6. For S. pseudopneumoniae strains CipR71 and 5305, only nucleotide changes are indicated, with nucleotides identical to R6 indicated by
asterisks, and deletions by dashes. (B) 5′ RACE PCR method. Agarose gel electrophoresis of PCR products of samples treated (+) or non-treated (–) with tobacco
acid pyrophosphatase (TAP). The band indicated by an arrowhead was extracted and sequenced. The chromatogram, sequence of the RNA oligonucleotide, star site,
and initiation codon of patA are indicated. (C) Structures of the regions marked with a black line in (A) as predicted by RNA-fold. The A shadowed in green indicates
the start site.
by the pressure exerted by the presence of FQs. These indels
would affect the stability of the stem-loop structure located
downstream of the −10 extended box of the promoter and
the mRNA start site. In fact, the predicted free energies for
this stem-loop structure were lower for S. pseudopneumoniae
isolates showing FQ efflux than for R6. The presence of these
alternative structures may influence the amount of the patAB
transcript under CPX-induction, as showed by RT-qPCR.
Differences between 5305 PatAB and S. suis SatAB protein
sequences were actually observed (84–86% similarity), where
non-conservative changes are concentrated in the two first
transmembrane alpha-helices (data not shown). This variability
may account for subtle differences in the FQ specificity of
homologs of this protein family potentially found in other
streptococci.
The genome of S. pneumoniae (de la Campa et al., 2017)
and of other streptococci (Martín-Galiano et al., 2017) is
organized in supercoiling domains that react coordinately to
Frontiers in Microbiology | www.frontiersin.org 8 October 2017 | Volume 8 | Article 2074
Alvarado et al. Fluoroquinolone Efflux in S. pseudopneumoniae
FIGURE 3 | Expression of hexA, patA and patB in R6-derivative
S. pneumoniae strains cultures exposed for 4 h to 0.5 × MIC of CPX. Data are
represented as ratios of expression under treated and non-treated cultures.
Values are mean ±SD of triplicates from three independent experiments.
Statistical significance with respect to R6 values by Student T-test: *P ≤ 0.05;
**P ≤ 0.01; ***P ≤ 0.001.
changes in supercoiling. Transcriptomic studies of S. pneumoniae
R6 showed that patA and patB are up-regulated in response
to DNA relaxation with novobiocin, an inhibitor of DNA
gyrase (Ferrándiz et al., 2010) and also by hyper-negative
supercoiling resulting from the inhibition of DNA topoisomerase
I by seconeolitsine (Ferrándiz et al., 2016a). Then, patA and
patB genes are located in chromosomal domains that are up-
regulated by global changes in DNA supercoiling. This fact
may reflect the high functional weight of this pump under
threatening conditions for the chromosome supercoiling state
caused by xenobiotics, such as FQs. Both ethidium bromide
and acriflavine, two substrates of the PatAB pump, are DNA
intercalants that alter the supercoiling of the DNA, causing
DNA relaxation (Ladoulis and Gill, 1970; Funatsuki et al., 1997).
In addition, acriflavine has been shown to inhibit the DNA
binding of gyrase (Mraheil et al., 2013). The effect of the
treatment with either of these compounds would cause DNA
relaxation, and, as in the case of inhibition of gyrase B with
novobiocin, the transcription of the patAB operon would be
enhanced. Although FQs do not change global supercoiling in
S. pneumoniae, local supercoiling changes have been shown
to alter the transcriptome of cultures treated with either LVX
(Ferrándiz and de la Campa, 2014) or MXF (Ferrándiz et al.,
2016b). Transcriptomic changes were different with these two
different FQs, but, in no case, the transcription of patAB was
affected. However, the transcriptional response to CPX, which
also differed from that of LVX or MOX, involves the up-
regulation of patAB (Marrer et al., 2006). We proposse that
local changes in DNA supercoiling would affect the stability of
the stem-loop structure located upstream patA (Glucksmann
et al., 1992; Lionnet et al., 2006), regulating the amount of
the transcripts of the downstream genes, either by regulation
of transcription or by processing of the mRNA. The role of
a transcriptional regulator recognizing the hairpin would be
compatible with this hypothesis.
The mutations described in this study did not confer clinical
FQ resistance by itself, since only conferred resistance to CPX
at 4µg/ml, in agreement with previous studies (Zhanel et al.,
2004; El Garch et al., 2010; Lupien et al., 2013). However, it has
been described that the presence of CPX efflux pumps favors
the acquisition of further mutations in the topoisomerase genes,
and that the combination of efflux and first-step mutations
can lead to MICs associated with treatment failure (Jumbe
et al., 2006). Then, the genetically close species S. pneumoniae
and S. pseudopneumoniae, shared the same mechanisms of
FQ resistance. Besides mutations in the quinolone-determining
regions of their topoisomerase genes, they also shared the up-
regulation of the PatAB pump as a mechanism of FQ-efflux.
In the same way as mutations in the topoisomerase genes can
be transferred between commensal streptococci of the mitis
group and S. pneumoniae (Ferrándiz et al., 2000; Balsalobre
et al., 2003), the mutations in the regulatory region of patA
could be exchanged, as shown in this study, and could therefore
contribute to a future increase of FQ resistance in S. pneumoniae.
These results reinforce the notion that S. pseudopneumoniae
can turn into an exchanger of resistance determinants to
S. pneumoniae, since both organisms share ecological niche (they
inhabit for long-term in the nasopharynx, Sakwinska et al.,
2014), and show high nucleotide identity and sinteny of flanking
regions, which would favor horizontal transfer of their genetic
material.
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